CD63 and prostate cancer: Moreover, colocalization experiments using prostate cancer cell-derived EVs confirmed that MB-targeted RNAs such as miR−141 co-localised with the exosomal marker CD63, supporting the biological relevance and detection specificity of the TCLN platform.